| Literature DB >> 36148089 |
David J Mazur-Hart1, Brannan E O'Neill1, Brandi W Pang1, Melanie H Hakar2, Matthew D Wood2, Sachin Gupta3, Christina M Sayama1, Jesse J Liu1, Aclan Dogan1.
Abstract
Objective We describe the first jugular foramen angiomatoid fibrous histiocytoma (AFH) case and the first treatment with preoperative endovascular embolization. AFH is a rare intracranial neoplasm, primarily found in pediatric patient extremities. With an increase in AFH awareness and a well-described genetic profile, intracranial prevalence has also subsequently increased. Study Design We compare this case to previously reported cases using PubMed/Medline literature search, which was performed using the algorithm ["intracranial" AND "angiomatoid fibrous histiocytoma"] through December 2020 (23 manuscripts with 46 unique cases). Patient An 8-year-old female presented with failure to thrive and right-sided hearing loss. Work-up revealed an absence of right-sided serviceable hearing and a large jugular foramen mass. Angiogram revealed primary arterial supply from the posterior branch of the ascending pharyngeal artery, which was preoperatively embolized. Intervention Gross total resection was performed via a translabyrinthine approach. Conclusion The case presented is unique; the first reported AFH at the jugular foramen and the first reported case utilizing preoperative embolization. Preoperative embolization is a relatively safe technique that can improve the surgeon's ability to perform a maximally safe resection, which may decrease the need for adjuvant radiation in rare skull base tumors in young patients. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: angiomatoid fibrous histiocytoma; jugular foramen; preoperative embolization; translabyrinthine approach
Year: 2022 PMID: 36148089 PMCID: PMC9489471 DOI: 10.1055/s-0042-1754320
Source DB: PubMed Journal: J Neurol Surg Rep ISSN: 2193-6358
Fig. 1Preoperative MRI showing a right jugular foramen heterogenous mass with solid and cystic components that appear hypervascular. ( A ) Axial T2. ( B ) Axial balanced fast field echo. ( C ) Coronal T1 with contrast. ( D ) Sagittal T1 with contrast.
Fig. 2Preoperative CT temporal bone protocol. No evidence of bone remodeling or osseous involvement.
Fig. 3Preoperative audiometry showing no serviceable hearing on the affected side.
Fig. 4Preoperative digital subtraction angiography. ( A ) Injection of the right common carotid artery during the arterial phase showing tumor blush from the posterior branch of the ascending pharyngeal artery. ( B ) Microcatheter injection of the ascending pharyngeal artery in the arterial phase.
Fig. 5Digital subtraction angiography showing preoperative embolization of the right ascending pharyngeal artery on a lateral projection of a right common carotid injection during the arterial phase. Embolization products are noted with no residual tumor blush.
Fig. 6Postoperative MRI showing gross total resection through a translabyrinthine approach with fat graft. ( A ) Axial T1 with contrast. ( B ) Coronal T1 with contrast.
Fig. 7Histological slides of this intracranial angiomatoid fibrous histiocytoma. ( A ) The lesion demonstrates a nodular proliferation with blood-filled pseudoangiomatous spaces and abundant hemosiderin deposition. The characteristic lymphoplasmacytic cuff often seen in this entity is absent in this case (x40 magnification). ( B ) Syncytial growth of bland spindled to epithelioid tumor cells; cytologic atypia is minimal, and mitotic figures are inconspicuous (x200 magnification). ( C ) The lesional cells show focal positivity for CD99 (x200 magnification) and ( D ) strong, diffuse staining for desmin (x200 magnification).
Fig. 8Fluorescence in situ hybridization analysis of tumor specimen showing gene rearrangement of EWSR1. (86% 1 red/ 1 green/ 1 yellow [normal signal pattern = 2 yellow]). Courtesy of Susan Olson, Ph.D., Knight Diagnostic Laboratories, Portland, Oregon, United States.
PubMed/Medline literature search using the algorithm [“intracranial” AND “angiomatoid fibrous histiocytoma”] through December 2020
| Series | Year | Age (years) | Sex | Presentation | Location | Size | Gene fusion | Adjuvant therapy | Follow-up | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| Dunham et al | 2008 | 25 | M | HA, N/V, right HH | Left occipital | 5.3 | EWS/ATF-1 | |||
| Ochalski et al | 2010 | 35 | M | HA, right facial weakness | Left mesial temporal | 0.5 × 0.5 | EWSR1 gene rearranged | Seven repeat surgeries for clot evacuation and/or debulking; two radiosurgeries | 49 | Deceased |
| Hansen et al | 2015 | 17 | F | HA, blurry vision, anemia, left arm hyper-reflexia | Bioccipital (extra-axial) | Repeat resection |
16
| Alive | ||
| Alshareef et al | 2016 | 58 | F | Weight loss, right facial weakness, right hearing loss | Meckel's cave | 6.1 × 4.8 × 2.9 | EWSR1 rearranged | 6 | Alive | |
| Kao et al | 2017 | 15 | F | Meninges | EWSR1-CREM | 17 | Alive | |||
| 23 | F | Meninges (occipital) | EWSR1-CREB1 | |||||||
| 20 | M | Frontal | EWSR1-CREB1 |
156
| Alive | |||||
| 12 | M | Seizure, tongue jittering | Left frontal | EWSR1-ATF1 | ||||||
| Spatz et al | 2018 | 22 | F | HA, seizure, left HH | Right occipital (extra-axial) | 3.1 × 3.1 × 2.6 | Repeat resection | 3 | Alive | |
| Bale et al | 2018 | 12 | M | HA | Left cerebellar (extra-axial) | 2.5 × 2.3 × 1.0 | EWSR1-CREB1 |
46
| Alive | |
| 14 | F | HA, N/V, diplopia | Left lateral ventricle | 3.8 × 3.6 × 3 | EWSR1-CREB1 |
47
| Alive | |||
| 18 | M | Seizure | Right frontal | 3.0 × 2.0 × 1.5 | EWSR1-CREM | 12 | Alive | |||
| Gareton et al | 2018 | 19 | M | Seizure | Right temporo-occipital (extra-axial) | EWSR1-CREM | API/AI type chemotherapy; radiation 61.2 Gy in 34 fractions; repeat resection for recurrence | 120 | Alive | |
| Sciot et al | 2018 | 17 | F | Seizure, right hemiparesis | Left frontal | 5.9 | ESWR1-ATF1 | Repeat resection for recurrence; radiation 59.4 Gy; additional resection for recurrence | 90 | Alive |
| Gunness et al | 2019 | 32 | F | HA, neck pain, papilledema | Right lateral ventricle | Repeat resection for recurrence; shunt for recurrent cyst | 24 | Alive | ||
| Konstantinidis et al | 2019 | 13 | F | HA, nystagmus | Right frontal (extra-axial) | EWSR1-ATF1 | Repeat resection for recurrence | 132 | Alive | |
| 12 | F | HA, N/V, blurry vision, right pronator drift | Left frontal | EWSR1-CREM | 28 | Alive | ||||
| Ghanbari et al | 2019 | 58 | F | Seizure, left hemiparesis | Right parietal (extra-axial) | 1.6 | EWSR1-CREB1 | 3 | Alive | |
| Aizpurua et al | 2019 | 9 | M | HA, N/V, transient vision loss, papilledema, left facial weakness, right uvula deviation | Left precentral gyrus | 2.5 × 2.0 × 1.8 | ESWR1-ATF1 | 12 | Alive | |
| White et al | 2019 | 9 | M | Fatigue, weight loss, abulia | Right frontal (extra-axial) | 2.1 | EWSR1-CREM | Repeat resection for recurrence; radiation 50 Gy in 26 fractions with a boost of 10 Gy to cavity | 6 | Alive |
| Bin Abdulqader et al | 2020 | 10 | M | HA, N/V, seizure, left hemiparesis, left facial weakness, left pronator drift | Bifrontal | 4 | EWSR1 rearranged | 3 | Alive | |
| 11 | F | Seizure | Right frontal (extra-axial) | 2.8 × 1.9 | EWSR1 rearranged | 5 | Alive | |||
| Komatsu et al | 2020 | 53 | F | HA, dizziness | Third ventricle | ESWR1-CREB1 | Radiation |
3
| Alive | |
| Domingo et al | 2020 | 36 | F | HA, N/V, diplopia, lower extremity weakness | Interhemispheric (extra-axial) | EWSR1-CREM | 3 | Alive | ||
| Ballester et al | 2020 | 67 | M | Confusion, expressive aphasia | Left temporal (extra-axial) | EWSR1-ATF1 | 3.5 | Alive | ||
| Valente Aguiar et al | 2020 | 58 | F | HA, N/V, confusion, gait imbalance, right hemiparesis | Left lateral ventricle | EWSR1-CREB1 | 6 | Alive | ||
| Ward et al | 2020 | 48 | F | HA | Left lateral ventricle | EWSR1-ATF1 | Repeat resection for recurrence; radiation for recurrence 35 Gy in 5 fractions | 16 | Alive | |
| Gilbert et al | 2020 | 52 | M | HA, N/V, imbalance, weight loss | Vermian (extra-axial) | EWSR1-CREM | 12 | Alive | ||
| Sloan et al | 2020 | 12 | M | Parietal | EWSR1-ATF1 | Radiation 59.4 Gy | 24 | Alive | ||
| 9 | F | Frontal | EWSR1-ATF1 | 63 | Deceased | |||||
| 24 | F | Occipital | EWSR1-ATF1 | |||||||
| 13 | F | Frontal | EWSR1-ATF1 | 24 | Alive | |||||
| 34 | F | Tentorium | EWSR1-ATF1 | 81 | Alive | |||||
| 17 | F | CPA | EWSR1-ATF1 | Radiation 59.4 Gy; chemotherapy | 27 | Deceased | ||||
| 70 | M | CPA with spinal dissemination | EWSR1-ATF1 | 1 | Deceased | |||||
| 17 | F | CPA | EWSR1-ATF1 | 13 | Alive | |||||
| 14 | F | Lateral ventricle | EWSR1-CREB1 | 59 | Alive | |||||
| 39 | F | Lateral ventricle | EWSR1-CREB1 | 6 | Alive | |||||
| 10 | M | Falx (parietal) | EWSR1-CREB1 | 57 | Alive | |||||
| 25 | F | CPA | EWSR1-CREB1 | 30 | Alive | |||||
| 14 | F | Parietal | EWSR1-CREB1 | 57 | Alive | |||||
| 15 | F | Spinal cord (thoracic) | EWSR1-CREM | Radiation | 30 | Alive | ||||
| 14 | F | Lateral ventricle | EWSR1-CREM | 38 | Alive | |||||
| 5 | F | Frontal | EWSR1-CREM | Chemotherapy | 11 | Alive | ||||
| 30 | M | Falx (frontal) | EWSR1-CREM | Radiation 54 Gy | 6 | Alive | ||||
| 4 | F | Occipital | FUS-CREM | 36 | Alive | |||||
| Authors | 2021 | 8 | F | N/V, right facial weakness, right hearing loss | Right jugular foramen | 3.2 × 2.7 × 2.6 | EWSR1 rearranged | 3 | Alive |
Abbreviations: API/AI, doxorubicin-cisplatin-ifosfamide; CPA, cerebellopontine angle; F, female; Gy, Gray; HA, headache; HH, homonymous hemianopsia; M, male; N, nausea; V, vomiting.
updated follow up from Ballester et al.
updated follow up from Valente Aguiar et al.
updated follow up from Sloan et al.
updated follow up from Bin Abdulqader et al.